INSMED INCORPORATED (NASDAQ:INSM) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0
INSMED INCORPORATED (NASDAQ:INSM) Files An 8-K Results of Operations and Financial Condition

INSMED INCORPORATED (NASDAQ:INSM) Files An 8-K Results of Operations and Financial Condition
ITEM 2.02 – Results of Operations and Financial Condition.

On October30, 2018,Insmed Incorporated issued a press release regarding its financial results for the three months and nine months ended September30, 2018. A copy of this press release is furnished herewith as Exhibit99.1 to this Item 2.02.

The information contained herein, including the Exhibitattached hereto, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

ITEM 9.01 – Financial Statements and Exhibits.

(d)Exhibits


INSMED Inc Exhibit
EX-99.1 2 a18-38205_1ex99d1.htm EX-99.1 Exhibit 99.1     Insmed Reports Third Quarter 2018 Financial Results and Provides Business Update   —Quarter Highlighted by U.S. FDA Approval of ARIKAYCE® (amikacin liposome inhalation suspension),…
To view the full exhibit click here

About INSMED INCORPORATED (NASDAQ:INSM)

Insmed Incorporated is a biopharmaceutical company. The Company operates in the segment of development and commercialization of inhaled therapies for patients with serious lung diseases. The Company’s lead product candidate, ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for patients with nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. The Company’s earlier stage pipeline includes INS1009, a nebulized prodrug formulation of treprostinil, a vasodilator of pulmonary arterial vascular beds. The Company is conducting a global Phase III clinical study of ARIKAYCE (the 212 or CONVERT study) in adult patients with NTM lung disease caused by Mycobacterium avium complex (MAC), the infective species in NTM lung disease in the United States, Europe and Japan.